Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing
Propanc to Host Call Highlighting Positive Results from Compassionate Use Study
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent
Propanc Engages Advisory Firm to Identify Strategic Investment Opportunities
Propanc’s Partner Pushing Boundaries to Circumvent Chemotherapy Resistance
Propanc Biopharma Confirms PRP Enhances Chemosensitivity
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia
Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030
MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a peer reviewed scientific article published by the Company and its research partners reached 3,000 reads on July 6, 2023, according to ResearchGate. The achievement demonstrates reader interest above 93% of published research articles over the past year, “therefore, this shows exceptional interest in our work and bodes well for our future, both clinical and academic,” according to Dr Julian Kenyon, MD, MB, ChB, Propanc’s Chief Scientific Officer.